share_log

Pfizer | SC TO-I: Issuer tender offer statement

Pfizer | SC TO-I: Issuer tender offer statement

辉瑞 | SC TO-I：投标报价单
美股SEC公告 ·  08/12 11:46

Moomoo AI 已提取核心信息

Pfizer Inc. has announced a voluntary Modification Offer for eligible employees holding performance share awards (PSAs) and total shareholder return units (TSRUs) granted in 2022 and 2023. The offer, which commenced on August 12, 2024, allows participants to modify their existing equity awards, extending the performance period by two years with adjusted terms. The offer aims to retain key talent by enhancing the incentive and retention value of these awards, following a decline in Pfizer's stock price which impacted the potential achievement of performance goals. The offer is open until 11:59 p.m., Eastern Time, on September 12, 2024, unless extended. Eligible participants include current active employees who have been continuously employed since July 24, 2024. The offer does not apply to independent board members. Pfizer's executive officers, including the CEO, are eligible to participate. The offer is not conditioned on a minimum number of acceptances and is subject to certain conditions outlined by the company. Pfizer's common stock is traded on the NYSE under the symbol 'PFE'.
Pfizer Inc. has announced a voluntary Modification Offer for eligible employees holding performance share awards (PSAs) and total shareholder return units (TSRUs) granted in 2022 and 2023. The offer, which commenced on August 12, 2024, allows participants to modify their existing equity awards, extending the performance period by two years with adjusted terms. The offer aims to retain key talent by enhancing the incentive and retention value of these awards, following a decline in Pfizer's stock price which impacted the potential achievement of performance goals. The offer is open until 11:59 p.m., Eastern Time, on September 12, 2024, unless extended. Eligible participants include current active employees who have been continuously employed since July 24, 2024. The offer does not apply to independent board members. Pfizer's executive officers, including the CEO, are eligible to participate. The offer is not conditioned on a minimum number of acceptances and is subject to certain conditions outlined by the company. Pfizer's common stock is traded on the NYSE under the symbol 'PFE'.
辉瑞公司已宣布为2022年和2023年获得绩效股票奖励（PSA）和总股东回报单位（TSRU）的合格员工提供自愿修改提议。该提议于2024年8月12日开始，允许参与者修改其现有的股权奖励，通过调整条款将业绩期延长两年。该提议旨在通过增加这些奖励的激励和保留价值来留住关键人才，因为辉瑞的股价下跌影响了业绩目标的实现。该提议将于2024年9月12日晚上11:59以前（美国东部时间）开放，除非延长。符合条件的参与者包括从2024年7月24日起连续雇用的现任员工。该提议不适用于独立董事会成员。辉瑞公司的行政人员，包括首席执行官，有资格参加。该提议不受最低接受数量的限制，并受公司列出的某些条件的约束。辉瑞的普通股在纽交所上市，标的为'PFE'。
辉瑞公司已宣布为2022年和2023年获得绩效股票奖励（PSA）和总股东回报单位（TSRU）的合格员工提供自愿修改提议。该提议于2024年8月12日开始，允许参与者修改其现有的股权奖励，通过调整条款将业绩期延长两年。该提议旨在通过增加这些奖励的激励和保留价值来留住关键人才，因为辉瑞的股价下跌影响了业绩目标的实现。该提议将于2024年9月12日晚上11:59以前（美国东部时间）开放，除非延长。符合条件的参与者包括从2024年7月24日起连续雇用的现任员工。该提议不适用于独立董事会成员。辉瑞公司的行政人员，包括首席执行官，有资格参加。该提议不受最低接受数量的限制，并受公司列出的某些条件的约束。辉瑞的普通股在纽交所上市，标的为'PFE'。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

独立文件8  查看翻译

独立文件9  查看翻译

独立文件10  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间